Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMPH.L Regulatory News (MPH)

  • There is currently no data for MPH

Interim Management Statement

8 Aug 2007 07:00

Marchpole Holdings PLC08 August 2007 MARCHPOLE HOLDINGS PLC ("Marchpole", "the Company" or "the Group") Interim Management Statement Marchpole Holdings plc (LSE: MPH), the fast growing fashion brand management group,has today published its first Interim Management statement as required by the revised Listing Authority disclosure rules. The statement relates to the first 13 weeks of the new financial year, representing the period 1 April to 1 July 2007. The Board continues to believe, as reported on 28 June 2007, that the Group is well placed to withstand the termination of the YSL licence. For the purposes of this statement it is meaningless to draw comparisons withthe same period last year because of the changes in the composition of theGroup, notably the end of the YSL licence and the acquisitions of Homebody andGreenmark. Sales of Emanuel Ungaro and Ungaro Homme in Europe, including the UK, areencouraging and in line with expectations, and we remain confident that theUngaro brand will prove to be an adequate replacement for YSL. Orders for thefirst line, Emanuel Ungaro, have received a significant boost from thesuccessful Paris fashion show held on 29 June and will be further augmented bythe opening of three new flagship stores in Bucharest, Azerbaijan and Colombiain Spring 2008. On a like for like basis sales of Jean Charles de Castelbajac have increased byfive per cent and royalty income has more than doubled reflecting the newlicence agreements put in place over the last year. During the period a newdistribution agreement has been signed for Japan with Coronet, a member of theItochu Group and a new partnership entered into with Lee Cooper, one of theworld's original denim companies. These will enhance earnings in 2008/2009. Boateng sales and orders have grown from last year when performance was blightedby legal disputes and market confusion over the continuation of the licence. Asreported previously this dispute was settled in Marchpole's favour by the Courtof Appeal in December 2006. Greenmark has been successfully integrated into the Marchpole business model andis performing ahead of expectations. The retail environment in North America continues to be difficult and sales byModa America are lower than for the same 13 week period last year. On thepositive side margins have improved as a result of Marchpole's sourcingcapabilities. Our balance sheet remains strong following the improvements made during the yearto 31 March 2007. There have been no significant changes in the financialposition of the Group since the publication of the Annual Report for the yearended 31 March 2007. The resignation of John Harrison as Group Finance Director was announced on 26July 2007. A replacement is being sought and John will remain with the Groupuntil that process has been completed. For further information please contact: Marchpole Holdings plc:Michael Morris 020 7908 7777Executive Deputy Chairman Bell Pottinger:David Rydell/Emma Kent/Amy Rajendran 020 7861 3232 Note to Editors: - Marchpole Holdings plc ("Marchpole") is an international brandmanagement group that designs, produces and sells clothing and accessories forten globally recognised fashion labels. It operates in all of the world's mainmarkets - UK, mainland Europe, Middle East, Asia and the USA - Its respected brands include Boateng, Emmanuel Ungaro, Ungaro Homme,Jean Charles de Castelbajac ("JCC"), Jean Charles de Castelbajac / Rossignol,Jean Charles de Castelbajac/Okaidi, Jean Charles de Castelbajac / New Era, JCDC/Lee Cooper and Homebody and Homemummy - Marchpole is renowned for its integrated approach to brandmanagement, taking a brand from concept to design studio to the customerinterface. - The Group has grown considerably in the past four years, from alicensee with one core licence (YSL menswear) - to today's internationalbusiness that manages its brands across a multitude of clothing lines andaccessories - Marchpole's acquisition (March 2006) of Moda America - the USlicensee for leading designer Emanuel Ungaro - provided further growthopportunities in the UK and America and strengthened the Company's relationshipwith Ungaro - The acquisition also enabled the Company to launch the Ungaro brand,already established by Marchpole in Europe and Asia, into the US, Canada andSouth America. The acquisition has also enabled the Company to re-launch JCCinto America. - In March 2007 Marchpole acquired 100% of Greenmark Limited, animporter and wholesaler of ladies shoes who currently supply in excess of 2.5million pairs of shoes per annum. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
11th Feb 20197:00 amRNSBoard Change
25th Jan 201911:10 amRNSPublication of F-4
18th Jan 20197:00 amRNSNew Deferred Bonus Plan
15th Jan 20197:00 amRNSBGS-649 Phase 2b data to be Presented at ENDO 2019
27th Dec 201810:02 amRNSDirector/PDMR Shareholding
24th Dec 20187:00 amRNSDirector/PDMR Shareholding
18th Dec 20187:00 amRNSPositive results from safety extension study
17th Dec 20186:25 pmRNSPositive results from safety extension study
17th Dec 20183:44 pmRNSAIM Rule 17 Disclosure Statement
10th Dec 20187:00 amRNSPresentation at BMO Healthcare Conference
5th Dec 20181:09 pmRNSProposed combination of Mereo and OncoMed
26th Nov 20187:00 amRNSIssue of Warrants
5th Nov 20187:00 amRNSFirst patient dosed in Phase 2 study
31st Oct 20183:37 pmRNSTotal Voting Rights
15th Oct 20187:00 amRNSCompletion of Patient Enrolment in Phase 2b study
1st Oct 201810:00 amRNSRevised Credit Facility and Issue of Warrants
3rd Sep 20187:00 amRNSBlock Listing Application
31st Aug 20186:25 pmRNSCorrection to Issued Share Capital
8th Aug 20187:00 amRNSMereo BioPharma Interim Results 2018
23rd Jul 20187:00 amRNSNotice of Interim Results
23rd Jul 20187:00 amRNSExercise of Options
21st Jun 201812:52 pmRNSResult of Annual General Meeting
29th May 20187:00 amRNSSuccessful Completion of PrimaryBid Offer
25th May 20184:31 pmRNSPrimaryBid.com Offer
22nd May 20187:00 amRNSNotice of AGM
27th Apr 20187:00 amRNSGrant of Options
26th Apr 20187:00 amRNSUpdate on Offering & Application to List on Nasdaq
9th Apr 201811:34 amRNSOffering and Application to List on Nasdaq
6th Apr 20181:03 pmRNSResult of General Meeting
3rd Apr 20187:00 amRNSPublication of Annual Report
26th Mar 20187:00 amRNSMereo BioPharma Files for Proposed Global Offering
23rd Mar 20187:00 amRNSFinal Results
20th Mar 20187:00 amRNSPUBLICATION OF NOTICE OF GENERAL MEETING
20th Mar 20187:00 amRNSMereo selected for oral presentation at ATS 2018
19th Mar 20187:00 amRNSMereo: Positive Top-Line Results for BGS-649
26th Feb 20187:00 amRNSMereo BioPharma Appoints Wills Hughes-Wilson
2nd Jan 20187:00 amRNS£10m credit facility drawdown & issue of warrants
18th Dec 20177:00 amRNSMereo Plans to Conduct Registered IPO in the US
13th Dec 20177:00 amRNSMereo BioPharma: Business Update
11th Dec 20177:00 amRNSPositive results from Phase 2 trial with BCT-197
13th Nov 20177:00 amRNSBPS-804 receives PRIME designation
6th Nov 201712:19 pmRNSHolding(s) in Company
30th Oct 20177:00 amRNSMereo announces agreement with AstraZeneca
18th Sep 20177:00 amRNSMereo to Present at Cantor Healthcare Conference
5th Sep 20177:00 amRNSUpdate on BGS-649 Phase 2b Study
22nd Aug 20179:17 amRNSIssue of Warrants
8th Aug 20177:12 amRNSInterim Results
3rd Jul 20177:00 amRNSNotice of Results
27th Jun 201711:23 amRNSResult of AGM
15th May 20177:00 amRNSUpdate on acumapimod Phase 2 Study

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.